오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium chloride; water for injections; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; water for injections; dibasic sodium phosphate; polysorbate 80 - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: sodium chloride; polysorbate 80; monobasic sodium phosphate monohydrate; dibasic sodium phosphate; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 100 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; water for injections; polysorbate 80; sodium chloride - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 40 microgram/ml - injection, solution - excipient ingredients: sodium chloride; monobasic sodium phosphate monohydrate; polysorbate 80; water for injections; dibasic sodium phosphate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 39.47 microgram/ml - injection, solution - excipient ingredients: monobasic sodium phosphate monohydrate; sodium chloride; dibasic sodium phosphate; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - darbepoetin alfa, quantity: 25 microgram/ml - injection, solution - excipient ingredients: water for injections; sodium chloride; dibasic sodium phosphate; polysorbate 80; monobasic sodium phosphate monohydrate - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignancies where anaemia develops as a result of concomitantly administered chemotherapy

이스라엘 - 영어 - Ministry of Health

amgen europe b.v. - adalimumab - solution for injection - adalimumab 50 mg / 1 ml - adalimumab - rheumatoid arthritisamgevita in combination with methotrexate is indicated for:• the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.• the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.axial spondyloarthritisankylosing spondylitis (as):amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.axial spondyloarthritis without radiographic evidence of as:amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as, but with objective signs of inflammation by radiological and/or laboratory tests including mri and serum crp levels, who have had an inadequate response to, or are intolerant to, non - steroidal anti-inflammatory drugs.psoriatic arthritisamgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease to improve physical function.psoriasisamgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.hidradenitis suppurativa (hs)amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic hs therapy.crohn’s diseaseamgevita is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn’s disease who have had an inadequate response to conventional therapy. amgevita is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.ulcerative colitisamgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6- mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.uveitisamgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroidsparing, or in whom corticosteroid treatment is inappropriate.intestinal behcet's diseaseamgevita is indicated for the treatment of intestinal behcet’s disease in patients who have had an inadequate response to conventional therapy.

캐나다 - 영어 - Health Canada

amgen canada inc - adalimumab - solution - 50mg - adalimumab 50mg - disease-modifying antirheumatic agents

캐나다 - 영어 - Health Canada

amgen canada inc - adalimumab - solution - 50mg - adalimumab 50mg - disease-modifying antirheumatic agents